Pharmafile Logo
Pharmafocus logo
Advanced Search

Alzheimer’s disease

Showing 15 posts of 38 posts found.

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

August 6, 2025
Mergers and Acquisitions Alzheimer's disease, Corporate, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology company specialising in neurodegenerative diseases. …

News
alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

July 30, 2025
Research and Development Alzheimer's disease, CE Mark approval, Eli Lilly, Neurology, Roche

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in vitro diagnostic regulation-certified blood-based diagnostic …

News
handshake

Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline

May 23, 2025
Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases

Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …

News

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months

April 10, 2025
Research and Development Alzheimer's disease, Neurology, TauRx Pharmaceutics, research and development

TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the progression of Alzheimer’s disease over …

News
alzheimers_brain

AC Immune’s pTau-targeting immunotherapy awarded Fast Track designation by FDA

July 26, 2024
Research and Development AC Immune, Alzheimer's disease, Neurology, clinical trials, fast track designation, immunotherapy, tau protein

Clinical-stage biopharmaceutical company AC Immune announced that the US Food and Drug Administration (FDA) has granted its Alzheimer’s disease (AD) …

News
dementia image

Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study

May 9, 2024
Research and Development Alzheimer's disease, Neurocrine Biosciences, Neurology, Nxera Pharma, Parkinson's disease, clinical trials, dementia, schizophrenia

Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational …

News
milad-fakurian-58z17lnvs4u-unsplash_2

PharmaKure and Universiti Teknologi MARA (UiTM) partner for Alzheimer’s diagnosis research

December 13, 2023
Medical Communications Alzheimer's disease, Neurology, PharmaKure, UiTM

PharmaKure and the faculty of pharmacy at the University Teknologi MARA (UiTM), Malaysia, have announced a research collaboration focusing on …

News

Halozyme and Acumen Pharmaceuticals enter collaboration for Alzheimer’s treatment

November 7, 2023
Business Services Acumen Pharmaceuticals, Alzheimer's disease, Halozyme, Neurology, collaboration

Halozyme Therapeutics has announced a global collaboration and non-exclusive license with Acumen Pharmaceuticals, providing Acumen with access to Halozyme’s Enhanze …

News

Allyx Therapeutics shares phase 1a trial data for Alzheimer’s treatment

October 31, 2023
Medical Communications Allyx Therpeutics, Alzheimer's disease, Neurology, clinical trial

Allyx Therapeutics has announced phase 1a single ascending dose study results at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) …

News

Alnylam shares positive results from phase 1 trial

July 17, 2023
Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial

Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …

News
Alzheimer's brain

FDA grants Alzheimer’s disease drug Leqembi full approval

July 7, 2023
Medical Communications Alzheimer's disease, Biogen, Eisai, FDA, Neurology

Japanese pharmaceutical company Eisai and US-based biotechnology company Biogen have announced that the US Food and Drug Administration (FDA) has …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

May 5, 2023
Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …

News
394px-ad_versus_co

Eisai and Biogen’s Alzheimer’s drug slows progression in Phase 2 trials

July 26, 2018
Research and Development Alzheimer's disease, BAN2401, Biodgen, Eisai, phase 2, research

An experimental drug developed by the Massachusetts-based multinational Biogen and their Japanese partner Eisai has been shown to significantly slow …

News
hands-981400_960_720

Alzheimer’s protein treatment that works in human cells

April 12, 2018
Research and Development Alzheimer's disease, Gladstone Institutes, biotech, drugs, pharma, pharmaceutical

One of the major stumbling blocks that science has come up against, when trying to develop potential treatments for Alzheimer’s …

News
brain-1787622_640

Antiepileptic drug use linked to increased risk of Alzheimer’s and dementia

April 10, 2018
Manufacturing and Production, Research and Development Alzheimer's disease, dementia, epilepsy, pharma

A new study conducted at the University of Eastern Finland and the German Center for Neurodegenerative Diseases (DZNE) has revealed …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026